#United States #Chicago #obesity #Kalohexis #MC3R/MC4R

Kalohexis Unveils Groundbreaking Approach to Weight Loss at ENDO 2026

Kalohexis Inc., a biotechnology firm currently in its clinical-stage, has recently made headlines at the Endocrine Society's Annual Meeting (ENDO 2026) held in Chicago. The company discussed a promising mechanism involving dual melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R) activation aimed at tackling obesity with increased safety and effectiveness. Presenting her findings, Dr. Jillian L. Seiler, the Lead Scientist at Endevica Bio—which spun out Kalohexis in March 2026—highlighted the significant potential of Kalohexis’ lead candidate, 710GO.

Dual Activation of MC3R/MC4R

The study showcased at the conference emphasized dual activation of MC3R and MC4R as a novel therapeutic strategy to promote weight loss. The research focused on nonhuman primates with diet-induced obesity, showing that 710GO led to an average weight reduction of 11.8% over a 15-week period. Importantly, this weight loss was characterized by preferential fat reduction while effectively preserving lean mass, minimizing the dreaded rebound effect commonly seen in weight-loss treatments.

With obesity being a significant public health concern, Kalohexis aims to provide an answer that not only meets metabolic needs but does so with enhanced safety. Traditional melanocortin agonists have been fraught with cardiovascular risks, but 710GO is devoid of such safety flags, a fact underscored by a lack of adverse effects on heart rate and blood pressure during telemetry monitoring.

Presentation Highlights

The oral presentation given by Dr. Seiler was part of ENDO’s focus on emerging pharmacotherapies, underscoring its scientific rigor and the relevance of its findings. Kalohexis is dedicated to continuing the research and development of 710GO, currently in a Phase 1 clinical trial aimed at validating its effectiveness in treating general obesity.

“I believe our research underscores the need for a paradigm shift,” stated Dr. Daniel Marks, Chief Scientific and Medical Officer of Kalohexis. He articulated how dual activation can yield meaningful weight loss, implying that innovations like 710GO could redefine treatment options in metabolic disease management.

Moreover, Dr. Seiler was selected to participate in the Rising Stars Power Talks—a competition spotlighting early-career researchers—further illustrating the impact of her work in the scientific community.

Looking Ahead

As Kalohexis moves forward, the implications of their research are broad. By leveraging the body’s natural metabolic pathways, the company seeks to enhance the quality of weight loss, thus providing a viable solution to the global obesity crisis. This dual activation mechanism could not only change the landscape of obesity treatment but may also apply broadly to various metabolic disorders.

Kalohexis isn’t just offering a new drug; they’re promoting a new philosophy in healthcare—one that prioritizes safety and long-term efficacy. The firm encourages continuous dialogue and exploration in this pivotal area of health care, striving towards a future where patients can attain and maintain healthier lives with accessible solutions. For more detailed insights into Kalohexis’ groundbreaking research, visit their official website at www.kalohexis.com.

As Kalohexis enters this challenging but exciting phase of their development, the scientific community eagerly anticipates further findings and breakthroughs.